CHENODIOL Drug Patent Profile

Which patents cover Chenodiol, and when can generic versions of Chenodiol launch?

Chenodiol is a drug marketed by Lgm Pharma and is included in one NDA.

The generic ingredient in CHENODIOL is chenodiol. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the chenodiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Chenodiol

A generic version of CHENODIOL was approved as chenodiol by LGM PHARMA on October 22^nd, 2009.

Summary for CHENODIOL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	4,544
DailyMed Link:	CHENODIOL at DailyMed

Recent Clinical Trials for CHENODIOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 2
National Center for Research Resources (NCRR)	Phase 2
Mayo Clinic	Phase 2

See all CHENODIOL clinical trials

Pharmacology for CHENODIOL

Drug Class

Bile Acid

US Patents and Regulatory Information for CHENODIOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lgm Pharma	CHENODIOL	chenodiol	TABLET;ORAL	091019-001	Oct 22, 2009		RX	No	Yes

Chenodiol Market Dynamics, Financial Trajectory, Patent Position, and Generic Risk

Last updated: August 18, 2026

Chenodiol is a small, highly specialized pharmaceutical market with two distinct commercial profiles. In the United States, chenodiol has legacy approval for dissolving radiolucent gallstones, but its commercial position is limited by ursodeoxycholic acid, surgery, and generic competition. In Europe, chenodeoxycholic acid was repositioned for cerebrotendinous xanthomatosis, or CTX, under the Leadiant CDCA brand and gained orphan-drug pricing. The resulting revenue opportunity is driven by treatment scarcity and high annual pricing rather than patient volume.

Public financial disclosures do not provide a reliable standalone revenue figure for chenodiol. The product is not a major disclosed revenue contributor for a large diversified pharmaceutical company, and Leadiant Biosciences is privately held. Its economic value is therefore best assessed through patient prevalence, regulatory exclusivity, pricing history, reimbursement pressure, and the potential for compounded or generic alternatives.

What is chenodiol and how is it used?

Chenodiol, also called chenodeoxycholic acid or CDCA, is a primary bile acid. It reduces hepatic cholesterol synthesis and changes bile composition, which can promote dissolution of selected cholesterol gallstones. It is also the deficient bile acid in CTX, a rare autosomal-recessive sterol-storage disorder caused by CYP27A1 mutations.

Attribute	Chenodiol profile
Active ingredient	Chenodeoxycholic acid
Main U.S. indication	Dissolution of selected radiolucent cholesterol gallstones
Main orphan indication	Cerebrotendinous xanthomatosis
Therapeutic category	Bile acid replacement and gallstone therapy
Common legacy strength	250 mg
U.S. regulatory route	Legacy full approval for gallstone treatment; later regulatory activity may depend on product and indication
European orphan product	Leadiant CDCA for CTX
Main substitute for gallstones	Ursodeoxycholic acid and surgery
Main substitute for CTX	No fully equivalent approved pharmacologic replacement in many markets

CTX is the more commercially important indication because treatment is generally long term and often lifelong. Early diagnosis and treatment can prevent or reduce progressive neurologic, tendon, ocular, gastrointestinal, and vascular complications. The patient population remains small, but the cost of untreated disease is high.

How large is the chenodiol market?

The addressable market is small by conventional pharmaceutical standards. CTX prevalence estimates vary substantially because the condition is underdiagnosed. Published estimates have generally placed prevalence between approximately 1 in 50,000 and 1 in 70,000 in some European populations, while genetic studies suggest that the true prevalence may be higher in selected populations (Mignarri et al., 2014).

The commercial market is constrained by four factors:

1. CTX has low diagnosed prevalence.
2. Diagnosis commonly occurs after years of nonspecific symptoms.
3. Treatment is chronic, but annual patient additions are limited.
4. Most gallstone patients do not require branded chenodiol.

The gallstone market is larger in patient count but less attractive financially. Chenodiol competes with ursodeoxycholic acid, laparoscopic cholecystectomy, and watchful waiting. The drug is generally reserved for selected patients with functioning gallbladders, radiolucent cholesterol stones, and contraindications to surgery or other treatment.

Estimated commercial segments

Segment	Patient volume	Duration	Pricing power	Competitive intensity
CTX	Very low	Lifelong	High in orphan markets	Moderate, subject to reimbursement
Gallstone dissolution	Larger	Months to years	Low to moderate	High
Compounded CDCA	Small but variable	Long term	Low	High where permitted
Investigational bile-acid uses	Uncertain	Indication-dependent	Unproven	Development-stage

No authoritative public source reports global chenodiol sales by indication. Company-level estimates that present a precise global market size should be treated cautiously unless they disclose patient counts, price assumptions, channel revenue, and geography.

What is the financial trajectory for chenodiol?

The product’s financial trajectory has followed a repositioning model rather than a volume-growth model.

Phase 1: Legacy gallstone medicine

Chenodiol was developed and approved for cholesterol gallstones decades ago. Its commercial value weakened as ursodeoxycholic acid became more widely used and laparoscopic cholecystectomy became standard care. The product’s chemical composition was also long known, limiting conventional composition-of-matter patent protection.

Phase 2: Orphan repositioning

The commercial thesis changed when CDCA was used as replacement therapy for CTX. In Europe, Leadiant obtained authorization for CDCA in CTX and marketed it as Leadiant CDCA. The orphan designation supported regulatory exclusivity and allowed pricing based on a rare-disease treatment model rather than a commodity bile-acid model (European Medicines Agency, 2017).

Phase 3: Pricing scrutiny

European authorities challenged the commercial sustainability of high orphan pricing. The Dutch Authority for Consumers and Markets fined Leadiant approximately €19.5 million in 2021 after finding that the company abused a dominant position through excessive pricing for CDCA used in CTX (Authority for Consumers and Markets, 2021). The case demonstrated the core tension in the business model: very low volume can support premium pricing, but price increases can trigger antitrust, reimbursement, and political intervention.

Phase 4: Restricted growth and market access pressure

Future revenue growth is more likely to come from diagnosis expansion and geographic access than from broad patient-volume growth. CTX screening, genetic testing, specialist referral, and earlier diagnosis can increase treated prevalence. Reimbursement agencies can offset that growth through price negotiations, hospital procurement, or authorization of compounded CDCA.

Public financial visibility remains limited:

Financial metric	Public position
Standalone chenodiol revenue	Not reliably disclosed
Leadiant CDCA revenue	Not publicly reported as a complete standalone series
Gross-to-net discounts	Not publicly disclosed
Patient count by country	Incomplete and inconsistent
Annual treatment price	Varies materially by country and reimbursement system
U.S. commercial sales	Not supported by a consistent public standalone disclosure
Global forecast certainty	Low without patient-level and price-level data

For investors, chenodiol is better analyzed as a niche specialty product with concentrated revenue exposure than as a conventional mass-market pharmaceutical.

What is the FDA regulatory status of chenodiol?

The FDA has recognized chenodiol as a drug for gallstone dissolution. The historical U.S. label covers selected patients with radiolucent stones in a functioning gallbladder. Treatment requires prolonged administration and imaging-based monitoring.

The U.S. regulatory situation is more complex than the European CTX pathway:

• The legacy U.S. indication is gallstone treatment.
• CTX use may involve off-label prescribing, special access, or a separate regulatory pathway depending on the product and date.
• FDA labeling and marketing status should be distinguished from European authorization for Leadiant CDCA.
• A product can have an FDA-listed historical approval while having limited commercial availability or a separate distributor arrangement.

The U.S. market has a lower barrier to substitution where physicians can use compounded or alternative sources of chenodeoxycholic acid. That risk is greater for a chemically defined small molecule than for a biologic.

What patents protect chenodiol?

The underlying chenodeoxycholic acid molecule is old and is not protected by a current composition-of-matter patent in the ordinary sense. Any commercial protection is more likely to arise from:

• CTX method-of-use patents;
• formulation and dosage patents;
• pharmaceutical-composition claims;
• manufacturing or purification processes;
• regulatory exclusivity;
• orphan-drug exclusivity;
• contractual distribution controls.

Patent protection should not be confused with orphan exclusivity. European orphan exclusivity can restrict approval of a similar product for the same indication even when no blocking patent remains. U.S. orphan exclusivity, where granted for a defined indication, also operates independently from patent rights.

Protection type	Strategic relevance
Composition of matter	Weak because CDCA is an old molecule
New formulation	Potentially relevant but narrow
CTX method of use	More important than gallstone claims
Manufacturing process	Relevant if purity or stereochemical control is difficult
U.S. Orange Book patent listing	Must be verified against the current FDA listing
European orphan exclusivity	Potentially more important than patent term for CTX
Data exclusivity	Depends on the approval pathway and jurisdiction

A current Orange Book review is necessary before assessing an ANDA Paragraph IV strategy. Patent numbers, expiration dates, and listing status can change through delisting, expiration, ownership transfers, or regulatory updates. No single legacy patent should be treated as the complete chenodiol estate.

When does chenodiol lose exclusivity?

There is no single global loss-of-exclusivity date for chenodiol.

United States

For the legacy gallstone indication, the molecule has long been exposed to generic-drug economics. The relevant questions are whether an active reference product remains listed, whether an ANDA can be filed, and whether any listed patents cover the proposed product or use.

For CTX, the timing depends on whether the indication has separate FDA approval and whether orphan exclusivity was granted. If CTX remains off label in the U.S., orphan exclusivity for that indication may not provide the same barrier as it does in Europe.

Europe

Leadiant CDCA received orphan authorization for CTX in the European Union. Orphan exclusivity generally runs for 10 years from authorization, subject to regulatory exceptions and possible extension for pediatric compliance. The practical protection period can differ by country because reimbursement decisions, hospital procurement, compounding rules, and national enforcement affect market access.

Practical conclusion

The meaningful exclusivity window is indication-specific:

Market	Key protection	Commercial implication
U.S. gallstones	Legacy approval, possible patents, generic pathway	High substitution risk
U.S. CTX	Regulatory status and any orphan designation	Must be assessed separately
EU CTX	Orphan exclusivity and national reimbursement	Stronger branded position, but price pressure
Non-EU markets	Local approval and patent rules	Highly fragmented
Compounding jurisdictions	Pharmacy access to CDCA	Can erode branded pricing

Are there Paragraph IV challenges or generic launch risks?

A publicly visible, widely documented Paragraph IV litigation campaign against chenodiol is not comparable to the major patent disputes surrounding blockbuster medicines. The more immediate competitive risks are regulatory and commercial:

• ANDA filing against a listed reference product;
• 505(b)(2) approval using published literature and existing safety data;
• pharmacy compounding;
• ex-U.S. sourcing;
• hospital procurement;
• physician substitution toward ursodeoxycholic acid where clinically appropriate.

A generic launch scenario would be most credible for the gallstone indication. CTX presents a harder commercial problem because market size is small, treatment is specialist-managed, and regulators may scrutinize equivalence, dose, purity, and continuity of supply.

Generic launch scenarios

Scenario	Probability assessment	Effect
Generic gallstone product	Commercially plausible	Significant price erosion
505(b)(2) CTX product	Possible but economically difficult	Moderate pressure
Compounded CDCA expansion	Plausible in price-sensitive markets	High local pressure
Biosimilar competition	Not applicable	CDCA is a small molecule
Parallel importation	Market-dependent	Moderate price pressure
New bile-acid therapy	Long-term possibility	Could reduce CDCA demand

Chenodiol is not a biologic. Biosimilar risk is therefore not relevant. The correct competitive framework is generic, hybrid application, compounding, and therapeutic substitution.

What formulations are protected by chenodiol patents?

The commercial product has historically been associated with oral capsules or tablets, commonly at a 250 mg strength. Formulation protection, if active, would likely focus on stability, dissolution, bioavailability, excipient selection, or dosing regimens rather than the molecule itself.

Formulation patents have limited strategic value when:

• the underlying product is simple to manufacture;
• clinicians can prescribe an alternative strength;
• pharmacies can compound the active ingredient;
• the therapeutic indication has a small patient population;
• regulatory exclusivity expires before a formulation patent becomes commercially meaningful.

Manufacturing barriers are also likely to be moderate rather than severe. CDCA is a defined small molecule, but commercial suppliers must meet pharmaceutical-grade standards for identity, purity, residual solvents, microbial quality, stability, and batch consistency. For CTX patients, reliable long-term supply can matter as much as nominal price.

Which companies are competing with or challenging chenodiol?

The competitive landscape is fragmented.

Direct competitors

• Leadiant Biosciences, through Leadiant CDCA and related specialty distribution activity.
• Generic or compounded chenodeoxycholic acid suppliers.
• Specialty pharmacies and hospital pharmacies that prepare or source CDCA.

Therapeutic competitors

• Ursodeoxycholic acid for selected gallstone patients.
• Laparoscopic cholecystectomy for gallstones.
• Supportive and disease-specific care for CTX complications.
• Potential future bile-acid replacement products.

No major biosimilar manufacturer is relevant because chenodiol is not a biologic. Large generic manufacturers could enter the gallstone segment if market size, reference-product status, and regulatory economics justify development. CTX entry is less attractive unless the entrant can secure reimbursement and a durable specialist distribution channel.

What litigation and settlement issues affect chenodiol?

The best-documented legal pressure has involved pricing rather than patent infringement. The Dutch competition authority’s action against Leadiant concerned alleged excessive pricing and abuse of dominance, not a conventional Paragraph IV patent dispute (Authority for Consumers and Markets, 2021).

No broadly reported, market-defining U.S. patent settlement has established a major delayed generic-entry date for chenodiol. Any settlement assessment should separate:

• patent litigation settlements;
• regulatory exclusivity;
• reimbursement agreements;
• hospital procurement contracts;
• antitrust investigations;
• access arrangements with compounding pharmacies.

The absence of a major public settlement does not eliminate entry risk. It indicates that commercial barriers may be more important than litigation barriers.

How strong is the chenodiol patent estate?

The patent estate is structurally weaker than the estate surrounding a new chemical entity.

Strengths

• CTX is a rare disease with concentrated specialist prescribing.
• Long-term treatment creates recurring demand.
• Orphan authorization can provide meaningful market protection.
• Diagnosis and treatment continuity can favor an established supplier.
• Regulatory and quality requirements can discourage small entrants.

Weaknesses

• The molecule is old.
• Gallstone therapy has substantial generic and therapeutic substitution risk.
• The patient population is small.
• Compounding can reduce pricing power.
• Method-of-use patents may be narrow and difficult to enforce against off-label use.
• Public pricing disputes can accelerate reimbursement intervention.

Overall, the commercial moat is stronger in European CTX treatment than in U.S. gallstone therapy. The moat is based primarily on orphan regulation, clinical familiarity, distribution, and reimbursement access, not on broad composition-of-matter patent rights.

What is the outlook for chenodiol revenue?

Revenue growth is likely to be uneven and geographically concentrated.

Upside drivers

• Higher CTX diagnosis rates.
• Genetic testing and newborn or family screening.
• Expansion into underdiagnosed markets.
• Continued lifelong treatment.
• Limited therapeutic substitutes for bile-acid replacement.
• Specialist and hospital reimbursement support.

Downside drivers

• National price controls.
• Compounding and generic entry.
• Antitrust intervention.
• Reimbursement restrictions.
• Low disease awareness.
• Product shortages or supply interruptions.
• Use of lower-cost alternatives where clinically acceptable.

The most likely financial profile is a small revenue base with high gross margin potential but significant policy and concentration risk. It is unlikely to become a large-volume product without expansion into new indications or a major improvement in CTX diagnosis.

Key Takeaways

• Chenodiol is a mature small molecule with limited value in the general gallstone market.
• Its principal commercial opportunity is long-term CTX treatment.
• European orphan authorization created substantially greater pricing power than the legacy U.S. gallstone indication.
• Public standalone sales and profit figures are unavailable, so precise revenue estimates are not supportable.
• Patent protection is likely weaker than regulatory exclusivity, clinical positioning, and distribution control.
• Biosimilar competition does not apply.
• Generic, 505(b)(2), compounding, and therapeutic-substitution risks are material.
• The most significant public legal issue has been excessive-pricing scrutiny, particularly in the Netherlands.
• Future growth depends more on diagnosis expansion and reimbursement access than on broad market penetration.

FAQs About Chenodiol Commercial and Patent Risk

Is chenodiol the same as chenodeoxycholic acid?

Yes. Chenodiol is the pharmaceutical name commonly used for chenodeoxycholic acid, also abbreviated CDCA.

Is chenodiol approved for CTX in the United States?

The U.S. regulatory position must be distinguished from the European authorization of Leadiant CDCA for CTX. U.S. approval and labeling should be checked by product, indication, and current FDA database status.

Can pharmacies compound chenodiol?

Compounding availability depends on local law, pharmacy capability, product sourcing, and regulatory restrictions. Compounding can reduce branded-product pricing power in some jurisdictions.

Is chenodiol protected by orphan-drug exclusivity?

Orphan exclusivity is indication- and jurisdiction-specific. European CTX authorization received orphan protection, while U.S. protection depends on the applicable FDA designation and approval status.

What is the main commercial threat to Leadiant CDCA?

The main threat is the combination of reimbursement and antitrust pricing pressure with compounded or generic CDCA, rather than biosimilar competition.

References

1. Authority for Consumers and Markets. (2021). ACM imposes fine on Leadiant for excessive price of medicine for rare disease. https://www.acm.nl/en/publications/acm-imposes-fine-leadiant-excessive-price-medicine-rare-disease

2. European Medicines Agency. (2017). Leadiant CDCA: EPAR - product information. https://www.ema.europa.eu/en/medicines/human/EPAR/leadiant-cdca

3. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

5. Mignarri, A., Dotti, M. T., Federico, A., & other authors. (2014). Cerebrotendinous xanthomatosis: Epidemiology, clinical manifestations, and treatment. Journal of Inherited Metabolic Disease, 37, 1-10.

6. National Organization for Rare Disorders. (n.d.). Cerebrotendinous xanthomatosis. https://rarediseases.org/rare-diseases/cerebrotendinous-xanthomatosis/